Unretouched clinical photos of actual LATISSE™ users. In
the clinical trial, 78% of LATISSE™ users experienced ≥
1-grade increase vs
18% for vehicle, and 33% experienced ≥ 2-grade increase
vs 1% for vehicle, on the 4-point Global Eyelash
Assessment (GEA) scale*
at week 16.¹ Individual results may vary.
LATISSE™ (bimatoprost ophthalmic solution) 0.03% is the
first and only FDA-approved prescription
treatment for hypotrichosis used to grow
eyelashes, making them longer, thicker, and darker.
Eyelash hypotrichosis is another name for having
inadequate or not enough eyelashes.
Important Safety Information
Do not use LATISSE™ solution if you are allergic to one
of its ingredients.
LATISSE™ solution is intended for use on the skin of the
upper eyelid margins at the base of the eyelashes. DO
NOT APPLY to the lower eyelid.
If you have a history of abnormal intraocular pressure (IOP),
you should only use LATISSE™ under the close supervision
of your physician.
LATISSE™ use may cause darkening of the eyelid skin
which may be reversible. Although not reported in
clinical studies, LATISSE™ use may also
cause increased brown pigmentation of the colored part
of the eye which is likely to be permanent.
You should tell your physician you are using LATISSE™
especially if you have a history of eye pressure
problems. You should also tell anyone
conducting an eye pressure screening that you are using
LATISSE™.
The most common side effects after using LATISSE™
solution are an itching sensation in the eyes and/or eye
redness. This was reported in
approximately 4% of patients. LATISSE™ solution may
cause other less common side effects which typically
occur on the skin close to where
LATISSE™ is applied, or in the eyes. These include skin
darkening, eye irritation, dryness of
the eyes, and redness of the eyelids.
Full prescribing information has been provided to your
doctor.
*Patent pending.
1.
Data on file, Allergan, Inc., 2008; Study No.
192024-032.
